New gel shows promise for speeding up wound healing in early trial

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria 1. Subjects scheduled to undergo excision of two or more clinically benign skin lesions (e.g., melanocytic nevi or seborrheic keratoses) that will result in at least two comparable acute cutaneous wounds suitable for study treatment. 2. Subject must be ≥ 18 years of age. 3. Subjects must be in generally good health, with no dermatologic or systemic condition that may impair normal wound healing, as determined by the Investigator. 4. Lesions selected for excision must be benign, confirmed clinically by the treating dermatologist or surgeon prior to the procedure. 5. Must be able and willing to provide informed consent prior to study participation. 6. Female subjects of childbearing potential must have a negative pregnancy test at day 0. They should agree to use highly effective methods of birth control, defined as those with failure less than 1%, such as implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices (IUD's), sexual abstinence, or a vasectomized partner. Exclusion Criteria 1. Any lesion scheduled for excision that is suspicious for malignancy or has not been clinically assessed as benign by the treating dermatologist or surgeon. 2. History of abnormal wound healing, including keloid formation, hypertrophic scarring, chronic non-healing wounds, or delayed healing after prior procedures. 3. Target ulcer shows any signs of infection (only non-infected ulcers are eligible). 4. Unable to tolerate multi-layer bandages or compression garments. 5. Decompensated congestive heart failure. 6. Active soft tissue or bone infection requiring antibiotics. 7. Skin cancer on the target limb within the last 24 months. 8. Actively receiving chemotherapy and/or radiation therapy for cancer. 9. Treatment with a serine/threonine-protein kinase BRAF inhibitor, including but not limited to Zelboraf® (vemurafenib), Tafinlar® (dabrafenib), BraftoviTM (encorafenib) or Nexavar® (sorafenib), within 30 days or 5 half-lives of the drug prior to Day 0, whichever is longer. 10. Blood chemistry and complete blood count (CBC) values from the most recent laboratory assessment performed within the past 12 monsth: 1. White Blood Cells (WBC) \< 1.5 x 109/L. 2. Absolute \< 0.9 x 109/L. 3. Platelet count \< 50 x 109/L. 4. Alanine aminotransferase \> 3 x upper limit of normal. 5. Aspartate aminotransferase \> 3 x upper limit of normal. 6. Serum albumin \<2.0 g/dL. 11. Current use of systemic corticosteroids \> 5 mg daily or equivalent within 4 weeks. 12. Currently pregnant or trying to become pregnant. 13. Inability or unwillingness to participate in all aspects of study protocol or as determined by the Investigator. 14. Known hypersensitivity to the ingredients of the study drug. 15. No known history of diabetis